What is "dinutuximab"

Dinutuximab (tradename Unituxin) is a monoclonal antibody that targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. It was approved for use, in combination with granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for high-risk neuroblastoma in pediatric patients; it received FDA approval in March 2015. It was initially developed by a federal agency, the U.S. National Cancer Institute in partnership with the Children’s Oncology Group. In 2010 United Therapeutics were under contract with NCI to "conduct late-stage clinical testing, and to manufacture and market the drug."